

Alok A Khorana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6945418/publications.pdf>

Version: 2024-02-01

271
papers

24,599
citations

14124

69
h-index

8433

152
g-index

276
all docs

276
docs citations

276
times ranked

17273
citing authors

#	ARTICLE	IF	CITATIONS
1	Vascular Imaging in the Asymptomatic <sc>High-risk</sc> Cancer Population. Journal of Ultrasound in Medicine, 2022, 41, 225-236.	0.8	1
2	Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI. Blood Advances, 2022, 6, 1212-1221.	2.5	9
3	Cancer-associated venous thromboembolism. Nature Reviews Disease Primers, 2022, 8, 11.	18.1	130
4	Acellular mucin in lymph nodes isolated from treatment-naïve colorectal cancer resections: a clinicopathologic analysis of 16 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, , .	1.4	0
5	Building a CAT clinic - real-world systems approaches to prevention and treatment. Thrombosis Research, 2022, 213, S84-S86.	0.8	0
6	Old is new again: Emergence of thromboembolic complications in cancer patients on immunotherapy. Thrombosis Research, 2022, 213, S51-S57.	0.8	6
7	Standardization of risk prediction model reporting in cancer-associated thrombosis: Communication from the ISTH-SSC subcommittee on hemostasis and malignancy. Journal of Thrombosis and Haemostasis, 2022, 20, 1920-1927.	1.9	3
8	Better prediction of stroke in atrial fibrillation with incorporation of cancer in CHA2DS2VASC score: CCHA2DS2VASC score. IJC Heart and Vasculature, 2022, 41, 101072.	0.6	5
9	2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncology, The, 2022, 23, e334-e347.	5.1	138
10	Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment—A report from ICTHIC 2021. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12744.	1.0	4
11	Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. Blood, 2021, 137, 2103-2113.	0.6	57
12	Prediction and Prevention of Cancer-Associated Thromboembolism. Oncologist, 2021, 26, e2-e7.	1.9	33
13	Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 822-829.	1.9	37
14	Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. , 2021, 9, e001719.		62
15	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Advances, 2021, 5, 927-974.	2.5	431
16	Similarities and perspectives on the two “Cancer and COVID-19. Journal of Thrombosis and Haemostasis, 2021, 19, 1161-1167.	1.9	10
17	Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis. Blood Advances, 2021, 5, 2055-2062.	2.5	8
18	Increased incidence of venous thromboembolism with cancer immunotherapy. Med, 2021, 2, 423-434.e3.	2.2	46

#	ARTICLE	IF	CITATIONS
19	Venous and Arterial Thromboembolism in Patients With Cancer. <i>JACC: CardioOncology</i> , 2021, 3, 173-190.	1.7	67
20	Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy. <i>Blood Cancer Journal</i> , 2021, 11, 121.	2.8	6
21	Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12549.	1.0	9
22	Future of Personalized Multimodality Management of Locally Advanced Rectal Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 403-404.	1.4	0
23	Risk Assessment for Cancer-Associated VTE. <i>JACC Asia</i> , 2021, 1, 271-273.	0.5	2
24	Thrombotic Complications Associated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 4606.	1.7	22
25	Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation. <i>Blood Advances</i> , 2021, 5, 4741-4751.	2.5	16
26	Healthcare costs of patients with cancer stratified by Khorana score risk levels. <i>Journal of Medical Economics</i> , 2021, 24, 866-873.	1.0	1
27	Racial disparities negatively impact outcomes in early-onset colorectal cancer independent of socioeconomic status. <i>Cancer Medicine</i> , 2021, 10, 7542-7550.	1.3	22
28	Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy. <i>Targeted Oncology</i> , 2021, 16, 813-821.	1.7	10
29	Risk of Venous Thromboembolism in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Blood</i> , 2021, 138, 3223-3223.	0.6	0
30	Abundance of B Cell Receptors Harboring Elongated Polytyrosine and Polyserine Rich Motifs within Their Heavy Chain CDR3 Distinguishes Catastrophic and Antiphospholipid Syndrome. <i>Blood</i> , 2021, 138, 2117-2117.	0.6	1
31	Risk of Venous Thromboembolism and Survival Outcomes in Patients with Lymphoma. <i>Blood</i> , 2021, 138, 4262-4262.	0.6	0
32	Publisher note. <i>Thrombosis Research</i> , 2021, 208, 173-175.	0.8	2
33	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 496-520.	0.8	971
34	Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Haematologica</i> , 2020, 105, 1436-1442.	1.7	19
35	Rethinking the approach to thrombosis in patients with cancer. <i>Vascular Medicine</i> , 2020, 25, 208-209.	0.8	2
36	Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 162-168.	1.9	55

#	ARTICLE	IF	CITATIONS
37	Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. <i>Cancer</i> , 2020, 126, 1640-1650.	2.0	28
38	Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: The Cleveland Clinic experience. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 651-659.	1.9	19
39	Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer. <i>Journal of Medical Economics</i> , 2020, 23, 323-329.	1.0	8
40	Evolving Treatment Options for Cancer-Related Venous Thromboembolism. <i>JACC: CardioOncology</i> , 2020, 2, 441-442.	1.7	4
41	Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. <i>Cancer Medicine</i> , 2020, 9, 6196-6204.	1.3	20
42	Prevention of venous thromboembolism in ambulatory patients with cancer. <i>ESMO Open</i> , 2020, 5, e000948.	2.0	16
43	Reply to S. Boutayeb et al. <i>JCO Oncology Practice</i> , 2020, 16, 525-525.	1.4	1
44	Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels. <i>Cancer Medicine</i> , 2020, 9, 8062-8073.	1.3	23
45	Preface to the Proceedings of the 10th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2020. <i>Thrombosis Research</i> , 2020, 191, S1-S2.	0.8	0
46	Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients: A Policy Statement From the American Heart Association. <i>Circulation</i> , 2020, 141, e914-e931.	1.6	77
47	Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. <i>Blood Advances</i> , 2020, 4, 2254-2260.	2.5	22
48	Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial. <i>TH Open</i> , 2020, 04, e107-e112.	0.7	16
49	Mechanisms and biomarkers of cancer-associated thrombosis. <i>Translational Research</i> , 2020, 225, 33-53.	2.2	50
50	The guidelines they are a changin'™. <i>European Journal of Internal Medicine</i> , 2020, 74, 5-7.	1.0	0
51	RNA expression and risk of venous thromboembolism in lung cancer. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 117-123.	1.0	9
52	Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 532-549.	1.0	10
53	Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. <i>Cancer</i> , 2020, 126, 1736-1748.	2.0	23
54	A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 3047-3060.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Bleeding Outcomes of Gastrointestinal Cancer Patients Treated with Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin. <i>Blood</i> , 2020, 136, 27-27.	0.6	5
56	Development and Baseline Characterization of a Thrombosis Risk Alert Tool: A Quality Assessment Project. <i>Blood</i> , 2020, 136, 18-19.	0.6	0
57	Risk of Recurrent Venous Thromboembolism and Bleeding in Patients with Cancer Associated Thrombosis. <i>Blood</i> , 2020, 136, 18-18.	0.6	1
58	Efficacy and Safety of Tinzaparin in CAT Patients with Metastatic Disease. <i>Blood</i> , 2020, 136, 33-34.	0.6	0
59	Thromboembolism in Patients with Advanced Renal Cell Carcinoma Treated with Immunotherapy. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
60	Frequency of Arterial Thromboembolic Events in Patients with Cancer Associated Venous Thromboembolism. <i>Blood</i> , 2020, 136, 37-37.	0.6	0
61	Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2141-2151.	1.9	41
62	Risks and Benefits of Anticoagulation in Cancer and Noncancer Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 629-637.	1.5	8
63	Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2019, 15, 454-457.	2.5	7
64	The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1772-1778.	1.9	107
65	Risk of Thrombosis in Cancer: Clinical Factors and Role of Primary Prophylaxis. <i>Cancer Treatment and Research</i> , 2019, 179, 55-68.	0.2	3
66	Predicting outcomes in patients with cancer and atrial fibrillation. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2019, 13, 175394471986067.	1.0	7
67	Modeling Complexity: The Case of Cancer-Related Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1713-1715.	1.8	1
68	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581.	5.1	458
69	Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2019, 9, 322-332.	1.1	121
70	Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants. <i>Journal of Medical Economics</i> , 2019, 22, 1134-1140.	1.0	12
71	Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2019, 37, 2082-2088.	0.8	135
72	Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 226-233.	1.0	14

#	ARTICLE	IF	CITATIONS
73	Bleeding incidence and risk factors among cancer patients treated with anticoagulation. American Journal of Hematology, 2019, 94, 780-785.	2.0	92
74	Does Sidedness Matter in Unresectable Colorectal Cancer?. Annals of Surgical Oncology, 2019, 26, 1588-1591.	0.7	1
75	A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer. Oncology, 2019, 96, 217-222.	0.9	14
76	Time to initial cancer treatment in the United States and association with survival over time: An observational study. PLoS ONE, 2019, 14, e0213209.	1.1	179
77	Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2019, 37, 153-164.	0.8	135
78	If Trousseau had a stroke. Blood, 2019, 133, 769-770.	0.6	2
79	Duration of anticoagulant therapy and VTE recurrence in patients with cancer. Supportive Care in Cancer, 2019, 27, 3833-3840.	1.0	9
80	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. New England Journal of Medicine, 2019, 380, 720-728.	13.9	520
81	The risk of recurrent VTE and major bleeding in a commercially insured population of cancer patients treated with anticoagulation. American Journal of Hematology, 2019, 94, E58-E61.	2.0	10
82	Thrombosis and Cancer. , 2019, , 430-447.		0
83	Anticoagulation in Cancer Patients: a Summary of Pitfalls to Avoid. Current Oncology Reports, 2019, 21, 18.	1.8	20
84	Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study.. Journal of Clinical Oncology, 2019, 37, 4016-4016.	0.8	8
85	Gastrointestinal Cancers and Thrombosis. , 2019, , 367-378.		0
86	Identifying miRNA Biomarkers and Predicted Targets Associated with Venous Thromboembolism in Colorectal Cancer Patients. Blood, 2019, 134, 3643-3643.	0.6	5
87	Clinical Outcomes of Cancer-Associated Thrombosis Beyond 6 Months of Anticoagulation. Blood, 2019, 134, 3458-3458.	0.6	5
88	Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism—Analysis of the CATCH Study. Thrombosis and Haemostasis, 2018, 118, 914-921.	1.8	37
89	Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 1246-1249.	1.9	140
90	Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. Oncologist, 2018, 23, 822-839.	1.9	24

#	ARTICLE	IF	CITATIONS
91	Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. <i>American Journal of Hematology</i> , 2018, 93, 664-671.	2.0	70
92	Risk prediction of cancer-associated thrombosis: Appraising the first decade and developing the future. <i>Thrombosis Research</i> , 2018, 164, S70-S76.	0.8	53
93	Multidisciplinary Conference and Clinical Management of Rectal Cancer. <i>Journal of the American College of Surgeons</i> , 2018, 226, 874-880.	0.2	21
94	Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies. <i>Thrombosis and Haemostasis</i> , 2018, 118, S23-S33.	1.8	12
95	Determination of the impact of melanoma surgical timing on survival using the National Cancer Database. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 40-46.e7.	0.6	95
96	Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). <i>Oncologist</i> , 2018, 23, 247-255.	1.9	63
97	Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. <i>Journal of Clinical Oncology</i> , 2018, 36, 2326-2347.	0.8	958
98	Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2545-2556.	0.8	204
99	Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	1.5	6
100	Artificial intelligence for cancer-associated thrombosis risk assessment – Author's reply. <i>Lancet Haematology</i> , 2018, 5, e391-e392.	2.2	5
101	Adjuvant Treatment in Potentially Curable Pancreatic Cancer. <i>Pancreas</i> , 2018, 47, e50-e52.	0.5	4
102	Prevalence of venous thromboembolism diagnosed in emergency department visits by cancer patients and associated healthcare resource utilization in the United States. <i>American Journal of Hematology</i> , 2018, 93, E207.	2.0	1
103	Do patients with pancreatic body or tail cancer benefit from adjuvant therapy? A cohort study. <i>Surgical Oncology</i> , 2018, 27, 245-250.	0.8	6
104	Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1891-1894.	1.9	325
105	Simplicity versus complexity: an existential dilemma as risk tools evolve. <i>Lancet Haematology</i> , 2018, 5, e273-e274.	2.2	14
106	Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 664-669.	1.0	47
107	Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). <i>Blood</i> , 2018, 132, LBA-1-LBA-1.	0.6	12
108	Economic Burden of Venous Thromboembolism in Cancer Patients – a Comparative Analysis between Matched Patients with Cancer with and without a Diagnosis of Venous Thromboembolism. <i>Blood</i> , 2018, 132, 366-366.	0.6	4

#	ARTICLE	IF	CITATIONS
109	Venous Thromboembolism in Cancer Patients Receiving Immunotherapy. <i>Blood</i> , 2018, 132, 2510-2510.	0.6	22
110	Healthcare Costs in Patients with Cancer Increase with Increasing Risk of Venous Thromboembolism. <i>Blood</i> , 2018, 132, 3799-3799.	0.6	1
111	An answer to "anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution". <i>American Journal of Hematology</i> , 2018, 93, E225-E227.	2.0	0
112	Venous Thromboembolism with Contemporary Lenalidomide-Based Regimens and Adequate Thromboprophylaxis in Newly Diagnosed Multiple Myeloma: A Systemic Review and Meta-Analysis. <i>Blood</i> , 2018, 132, 4835-4835.	0.6	0
113	Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. <i>Thrombosis Research</i> , 2017, 151, 89-95.	0.8	109
114	Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool. <i>American Journal of Hematology</i> , 2017, 92, 501-507.	2.0	60
115	Cancer and Venous Thromboembolic Disease: A Review. <i>Oncologist</i> , 2017, 22, 199-207.	1.9	160
116	Risk Assessment Scores for Cancer-Associated Venous Thromboembolic Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 469-478.	1.5	22
117	The association between race and venous thromboembolism risk after initiation of chemotherapy: An analysis of the "SAVE" "ONCO" trial control arm. <i>American Journal of Hematology</i> , 2017, 92, E101-E103.	2.0	7
118	Multidisciplinary Clinics for Colorectal Cancer Care Reduces Treatment Time. <i>Clinical Colorectal Cancer</i> , 2017, 16, 366-371.	1.0	27
119	Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 14-22.	1.0	109
120	Usefulness of CHADS2 and CHA2DS2-VASc Scores for Stroke Prediction in Patients With Cancer and Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 2182-2186.	0.7	51
121	Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection. <i>Journal of Digestive Diseases</i> , 2017, 18, 642-649.	0.7	7
122	Identifying predictors for bleeding in hospitalized cancer patients: A cohort study. <i>Thrombosis Research</i> , 2017, 158, 38-43.	0.8	22
123	Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE. <i>Clinical Therapeutics</i> , 2017, 39, 1396-1408.	1.1	6
124	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2135-2145.	1.8	53
125	American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 598-599.	0.2	15
126	Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study. <i>JNCI Cancer Spectrum</i> , 2017, 1, pxx009.	1.4	6

#	ARTICLE	IF	CITATIONS
127	Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 388-391.	2.5	19
128	Reply to R. Fonseca et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 2218-2219.	0.8	0
129	Reply to A. Wang-Gillam et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 690-691.	0.8	0
130	Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1078-1085.	0.8	60
131	Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 2324-2328.	0.8	160
132	American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations. <i>Journal of Clinical Oncology</i> , 2017, 35, 2203-2208.	0.8	167
133	Innovations in American Society of Clinical Oncology Practice Guideline Development. <i>Journal of Clinical Oncology</i> , 2016, 34, 3213-3220.	0.8	14
134	Tinzaparin vs Warfarin for Acute Venous Thromboembolismâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 200.	3.8	0
135	Predictors of recurrent venous thromboembolism and bleeding on anticoagulation. <i>Thrombosis Research</i> , 2016, 140, S93-S98.	0.8	26
136	Venous thromboembolism following hematopoietic stem cell transplantationâ€”a systematic review and meta-analysis. <i>Annals of Hematology</i> , 2016, 95, 1457-1464.	0.8	48
137	Reducing Unplanned Medical Oncology Readmissions by Improving Outpatient Care Transitions: A Process Improvement Project at the Cleveland Clinic. <i>Journal of Oncology Practice</i> , 2016, 12, e594-e602.	2.5	40
138	Centralizing care of cancer-associated thromboembolism: The Cleveland Clinic experience. <i>Thrombosis Research</i> , 2016, 147, 102-103.	0.8	9
139	International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2016, 17, e452-e466.	5.1	315
140	Molecular characteristics of biliary tract cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 111-118.	2.0	29
141	Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?. <i>Thrombosis Research</i> , 2016, 145, 51-53.	0.8	122
142	Enhancing Value for Patients With Cancer: Time to Treatment as a Surrogate for Integrated Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 115-116.	2.3	13
143	Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2784-2796.	0.8	267
144	Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. <i>Cancer Research</i> , 2016, 76, 3671-3675.	0.4	27

#	ARTICLE	IF	CITATIONS
145	Advances in adjuvant therapy of colon cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2016, 27, 204-212.	0.2	0
146	Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2654-2668.	0.8	292
147	Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2541-2556.	0.8	302
148	Thromboprophylaxis in Cancer Patients. , 2016, , 97-109.		0
149	Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism. <i>Neuro-Oncology Practice</i> , 2016, 3, 87-96.	1.0	26
150	A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality. <i>Oncologist</i> , 2016, 21, 861-867.	1.9	54
151	Guidance for the prevention and treatment of cancer-associated venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 81-91.	1.0	169
152	Prospective Clinical Study of Precision Oncology in Solid Tumors. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	70
153	Recurrent venous thromboembolism in glioblastoma. <i>Thrombosis Research</i> , 2016, 137, 184-188.	0.8	45
154	Safety of Anticoagulant Therapies for Treatment of Venous Thromboembolism in Patients with Cancer. <i>Blood</i> , 2016, 128, 1178-1178.	0.6	2
155	Predictors of Venous Thromboembolism in Colorectal Cancer: Results from a Global Prospective Study. <i>Blood</i> , 2016, 128, 1422-1422.	0.6	1
156	Major Bleeding Events Among Cancer and Non-Cancer Patients Taking Rivaroxaban for Venous Thromboembolism Treatment in a Department of Defense Health System Cohort. <i>Blood</i> , 2016, 128, 1447-1447.	0.6	4
157	Duration of anticoagulant therapy and VTE recurrence in patients with cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10112-10112.	0.8	1
158	Predicting venous thromboembolism in hospitalized cancer patients: a risk assessment tool.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6598-6598.	0.8	3
159	Idarucizumab: the first FDA-approved direct oral anticoagulant reversal agent. <i>Journal of Community and Supportive Oncology</i> , 2016, 14, 6-7.	0.1	0
160	The wacky hypercoagulable state of malignancy. <i>Blood</i> , 2015, 126, 430-431.	0.6	7
161	A health systems approach to risk stratification. <i>Thrombosis Research</i> , 2015, 136, 1049-1050.	0.8	0
162	Laparoscopy mitigates adverse oncological effects of delayed adjuvant chemotherapy for colon cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 493-499.	1.3	6

#	ARTICLE	IF	CITATIONS
163	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. <i>Journal of Clinical Oncology</i> , 2015, 33, 654-656.	0.8	911
164	Predicting early mortality in resectable pancreatic adenocarcinoma: A cohort study. <i>Cancer</i> , 2015, 121, 1779-1784.	2.0	28
165	Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 880-883.	1.9	96
166	Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 325-326.	1.9	3
167	Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 677.	3.8	530
168	Cancer Workup after Unprovoked Clot "Less Is More". <i>New England Journal of Medicine</i> , 2015, 373, 768-769.	13.9	6
169	Integrating Systemic and Surgical Approaches to Treating Metastatic Colorectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 199-214.	0.6	7
170	Current Practice Patterns and Patient Persistence on Anticoagulant Treatments for Cancer-Associated Thrombosis. <i>Blood</i> , 2015, 126, 626-626.	0.6	7
171	Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: The CATCH study. <i>Journal of Clinical Oncology</i> , 2015, 33, 9621-9621.	0.8	11
172	Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated with Mortality in Patients with Prostate Cancer. <i>PLoS ONE</i> , 2014, 9, e94048.	1.1	36
173	The Reply. <i>American Journal of Medicine</i> , 2014, 127, e35.	0.6	0
174	Risk Assessment for Thrombosis in Cancer. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 319-324.	1.5	40
175	Screening high-risk cancer patients for VTE: A prospective observational study. <i>Thrombosis Research</i> , 2014, 134, 1205-1207.	0.8	39
176	Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1746-1749.	1.9	36
177	Pancreatic Adenocarcinoma: Treating a Systemic Disease With Systemic Therapy. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju011-dju011.	3.0	141
178	Pattern of Frequent But Nontargeted Pharmacologic Thromboprophylaxis for Hospitalized Patients With Cancer at Academic Medical Centers: A Prospective, Cross-Sectional, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1792-1796.	0.8	45
179	Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis. <i>Thrombosis Research</i> , 2014, 134, 1214-1219.	0.8	154
180	Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1928-1931.	1.9	55

#	ARTICLE	IF	CITATIONS
181	Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. <i>British Journal of Cancer</i> , 2014, 111, 430-436.	2.9	56
182	The Reply. <i>American Journal of Medicine</i> , 2014, 127, e13.	0.6	0
183	Lack of Evidence to Support Thromboprophylaxis in Hospitalized Medical Patients with Cancer. <i>American Journal of Medicine</i> , 2014, 127, 82-86.e1.	0.6	132
184	Risk stratification strategies for cancer-associated thrombosis: an update. <i>Thrombosis Research</i> , 2014, 133, S35-S38.	0.8	93
185	Correspondence. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 452-453.	2.3	1
186	Decision Time. <i>Annals of Internal Medicine</i> , 2014, 160, 436-437.	2.0	0
187	A Randomized Trial of Long-Term Tinzaparin, a Low Molecular Weight Heparin (LMWH), Versus Warfarin for Treatment of Acute Venous Thromboembolism (VTE) in Cancer Patients - the CATCH Study. <i>Blood</i> , 2014, 124, LBA-2-LBA-2.	0.6	15
188	CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. <i>BMC Cancer</i> , 2013, 13, 284.	1.1	61
189	Targeted prophylaxis in cancer: the evidence accumulates. <i>Internal and Emergency Medicine</i> , 2013, 8, 187-189.	1.0	11
190	Prevalence and Clinical Significance of Incidental and Clinically Suspected Venous Thromboembolism in Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2013, 14, 713-718.	1.1	65
191	Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1760-1765.	1.9	143
192	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2013, 31, 2189-2204.	0.8	717
193	Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. <i>Thrombosis Research</i> , 2013, 132, 180-184.	0.8	111
194	International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 56-70.	1.9	469
195	International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 71-80.	1.9	252
196	Thrombosis and Cancer. , 2013, , 408-422.		0
197	Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. <i>Cancer</i> , 2013, 119, 648-655.	2.0	356
198	Reply to T.H. Oo. <i>Journal of Clinical Oncology</i> , 2013, 31, 4381-4382.	0.8	3

#	ARTICLE	IF	CITATIONS
199	Venous Thromboembolism Prevention in Cancer Outpatients. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1431-1438.	2.3	17
200	Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. ClinicoEconomics and Outcomes Research, 2013, 5, 101.	0.7	107
201	Thrombosis and Cancer: Emerging Data for the Practicing Oncologist. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e337-e345.	1.8	16
202	Thrombosis and Cancer: Emerging Data for the Practicing Oncologist. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e337-e345.	1.8	9
203	Can EGFR mutation status evolve with chemotherapy?. Chinese Clinical Oncology, 2013, 2, 1.	0.4	11
204	Preventing VTE in Outpatients With Cancer. Chest, 2012, 142, 265-266.	0.4	3
205	Risk assessment for cancer-associated thrombosis: What is the best approach?. Thrombosis Research, 2012, 129, S10-S15.	0.8	35
206	Diabetes Mellitus Is Associated With the Presence of Metastatic Spread at Disease Presentation in Hepatocellular Carcinoma. Cancer Investigation, 2012, 30, 698-702.	0.6	9
207	Incidental venous thromboembolism in oncology patients. Journal of Thrombosis and Haemostasis, 2012, 10, 2602-2604.	1.9	70
208	Cancer-associated thrombosis: updates and controversies. Hematology American Society of Hematology Education Program, 2012, 2012, 626-630.	0.9	57
209	The use of weighted and scored risk assessment models for venous thromboembolism. Thrombosis and Haemostasis, 2012, 108, 1072-1076.	1.8	40
210	Cancer and coagulation. American Journal of Hematology, 2012, 87, S82-7.	2.0	68
211	Cancer-associated thrombosis: updates and controversies. Hematology American Society of Hematology Education Program, 2012, 2012, 626-30.	0.9	34
212	Cancer-associated thrombosis: an update. Drug Discovery Today Disease Mechanisms, 2011, 8, e39-e45.	0.8	4
213	Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thrombosis and Haemostasis, 2011, 106, 371-378.	1.8	124
214	Risk Assessment and Prophylaxis for VTE in Cancer Patients. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 789-797.	2.3	37
215	Can Literature Enhance Oncology Training? A Pilot Humanities Curriculum. Journal of Clinical Oncology, 2011, 29, 468-471.	0.8	13
216	Higher Incidence of Venous Thromboembolism in the Outpatient Versus the Inpatient Setting Among U.S. Cancer Patients. Blood, 2011, 118, 674-674.	0.6	17

#	ARTICLE	IF	CITATIONS
217	Venous Thromboembolism in Patients with Hematologic Malignancies. , 2011, , 449-459.		0
218	Venous Thromboembolism (VTE) In Hospitalized Patients: What Proportion Is Attributable to Malignancy?. Blood, 2011, 118, 5250-5250.	0.6	2
219	The role of thromboprophylaxis in cancer patients: emerging data. Current Opinion in Hematology, 2010, 17, 450-456.	1.2	9
220	Physician As Typist. Journal of Clinical Oncology, 2010, 28, 3899-3900.	0.8	11
221	Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Groupâ€œDirected Intergroup Trial S0205. Journal of Clinical Oncology, 2010, 28, 3605-3610.	0.8	570
222	A Phase II Study of Weekly Docetaxel in Combination with Capecitabine in Advanced Gastric and Gastroesophageal Adenocarcinomas. Oncology, 2010, 78, 125-129.	0.9	17
223	A Computerized Prompt for Thromboprophylaxis in Hospitalized Cancer Patients. Thrombosis Research, 2010, 126, 32-34.	0.8	5
224	Venous thromboembolism and prognosis in cancer. Thrombosis Research, 2010, 125, 490-493.	0.8	319
225	Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thrombosis Research, 2010, 126, 113-118.	0.8	115
226	Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thrombosis Research, 2010, 125, S1-S7.	0.8	82
227	Cancer Patients and Awareness of Venous Thromboembolism. Cancer Investigation, 2010, 28, 44-45.	0.6	33
228	Symptomatic and Incidental Thromboses Are Both Associated with Mortality In Pancreatic Cancer. Blood, 2010, 116, 3167-3167.	0.6	1
229	A Predictive Risk Score for Cancer-Associated Thrombosis: Role of Screening In A Prospective Study. Blood, 2010, 116, 3173-3173.	0.6	10
230	The role of the oncologist in the management of VTE. Clinical Advances in Hematology and Oncology, 2010, 8, 524-6.	0.3	0
231	New Insights Into Cancer-Associated Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 316-320.	1.1	70
232	Cancer, Clots and Consensus: New Understanding of an Old Problem. Journal of Clinical Oncology, 2009, 27, 4821-4826.	0.8	149
233	Cancer and thrombosis: implications of published guidelines for clinical practice. Annals of Oncology, 2009, 20, 1619-1630.	0.6	101
234	Risk stratification for cancer-associated venous thromboembolism. Best Practice and Research in Clinical Haematology, 2009, 22, 35-47.	0.7	35

#	ARTICLE	IF	CITATIONS
235	Tissue Factor and VEGF Expression in Prostate Carcinoma: A Tissue Microarray Study. <i>Cancer Investigation</i> , 2009, 27, 430-434.	0.6	18
236	Cancer and Thrombosis: Back to the Future<i>Renewed Interest in an Old Problem</i>. <i>Cancer Investigation</i> , 2009, 27, 472-473.	0.6	8
237	Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. <i>Thrombosis Research</i> , 2009, 123, S18-S21.	0.8	64
238	Assessing Risk of Venous Thromboembolism in the Patient With Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4839-4847.	0.8	446
239	Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action. <i>Journal of Clinical Oncology</i> , 2009, 27, 4919-4926.	0.8	162
240	Reply to Frequency, Risk Factors, and Trends for Venous Thromboembolism Among Hospitalized Cancer Patients. <i>Cancer</i> , 2008, 113, 224-224.	2.0	1
241	Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. <i>Thrombosis Research</i> , 2008, 122, 299-306.	0.8	99
242	Blood Transfusions, Thrombosis, and Mortality in Hospitalized Patients With Cancer. <i>Archives of Internal Medicine</i> , 2008, 168, 2377.	4.3	304
243	Disorientation. <i>Health Affairs</i> , 2008, 27, 1154-1159.	2.5	1
244	Development and validation of a predictive model for chemotherapy-associated thrombosis. <i>Blood</i> , 2008, 111, 4902-4907.	0.6	1,682
245	Venous Thromboembolism Risk Model Predicts Early Progression and Overall Mortality in Cancer Patients Receiving Chemotherapy. <i>Blood</i> , 2008, 112, 172-172.	0.6	9
246	Venous Thromboembolism and Anticoagulation. <i>Translational Medicine Series</i> , 2008, , 1-29.	0.0	0
247	Ambulatory Patient Preference for VTE Prophylaxis. <i>Blood</i> , 2008, 112, 4709-4709.	0.6	0
248	The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: Strategies for Improving VTE Prophylaxis in Hospitalized Cancer Patients. <i>Oncologist</i> , 2007, 12, 1361-1370.	1.9	116
249	Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 2870-2875.	3.2	338
250	Approaches to risk-stratifying cancer patients for venous thromboembolism. <i>Thrombosis Research</i> , 2007, 120, S41-S50.	0.8	31
251	American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5490-5505.	0.8	875
252	A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment. <i>Cancer</i> , 2007, 110, 1149-1161.	2.0	198

#	ARTICLE	IF	CITATIONS
253	Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. <i>Cancer</i> , 2007, 110, 2339-2346.	2.0	662
254	Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. <i>Liver Transplantation</i> , 2007, 13, 807-813.	1.3	64
255	Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 632-634.	1.9	1,309
256	Venous thromboembolism in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1029-1033.	0.6	80
257	FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. <i>Blood</i> , 2006, 107, 126-131.	0.6	82
258	Thromboembolism in Hospitalized Neutropenic Cancer Patients. <i>Journal of Clinical Oncology</i> , 2006, 24, 484-490.	0.8	424
259	Vascular Endothelial Growth Factor and Predict Adjuvant Therapy Outcomes in Resected Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2005, 9, 903-911.	0.9	27
260	Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. <i>Cancer</i> , 2005, 104, 2822-2829.	2.0	475
261	Concordance. <i>Health Affairs</i> , 2005, 24, 511-515.	2.5	3
262	The Influence of Host Response on Colorectal Cancer Prognosis. <i>Clinical Colorectal Cancer</i> , 2004, 4, 38-45.	1.0	37
263	Pancreatic cancer and thromboembolic disease. <i>Lancet Oncology</i> , The, 2004, 5, 655-663.	5.1	229
264	Venous Thromboembolic Events in Patients with Diffuse Large B cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2004, 104, 4542-4542.	0.6	2
265	Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma. <i>Cancer</i> , 2003, 97, 960-968.	2.0	147
266	Malignancy, thrombosis and Trousseau: the case for an eponym. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2463-2465.	1.9	116
267	A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. <i>Cancer Gene Therapy</i> , 2003, 10, 251-259.	2.2	61
268	At The End Of A Day. <i>Health Affairs</i> , 2003, 22, 239-243.	2.5	0
269	Heparin Inhibition of Endothelial Cell Proliferation and Organization Is Dependent on Molecular Weight. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 2110-2115.	1.1	126
270	A Phase II Multicenter Study of CAMPATH-1H Antibody in Previously Treated Patients with Nonbulky Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2001, 41, 77-87.	0.6	48

#	ARTICLE	IF	CITATIONS
271	Author's Reply to Åžener and Begijanashvili: "Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy" Targeted Oncology, 0, , .	1.7	0